Translate this page into:
Letters to Editor
doi:
10.4103/2278-330X.130469
Myeloma and diabetes mellitus
1
Primary Care Unit, KMT Center, Bangkok, Thailand
2
Visiting Professor, Hainan Medical University, China
3
Visiting Professor, Faculty of Medicine, University of Nis, Serbia
*Corresponding author: Dr. Sora Yasri. sorayasri@outlook.co.th
MedIntel Services Pvt Ltd. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/.)
Disclaimer:
This article was originally published by Thieme Medical and Scientific Publishers Pvt. Ltd. and was migrated to Scientific Scholar after the change of Publisher.
This article was originally published by Thieme Medical and Scientific Publishers Pvt. Ltd. and was migrated to Scientific Scholar after the change of Publisher.
References
- Ali MA, Ahmed YA, Ibrahim A. Clinical challenges: Myeloma and concomitant type 2 diabetes. South Asian J Cancer 2013;2:290-5.
- Ahmed YA, Eltayeb A. Clinical challenges: Myeloma and concomitant type 2 diabetes. Int J Hematol Oncol Stem Cell Res 2013;7:34-41.
- Pospísilová Y, Adam Z. Disorder of glucose metabolism regulation in patients with multiple myeloma treated with high doses of corticosteroids at our clinic in 2004. Vnitr Lek 2007;53:18-23.
- Snowden JA, Greaves M, Page K. Reversal of diabetes associated with escape of myeloma: Evidence for inappropriate IGF-II secretion. Br J Haematol 1994;87:202-4.